# Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies

> **NCT05983146** · PHASE1 · WITHDRAWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.**

## Conditions studied

- Advanced Malignant Cancer

## Interventions

- **DRUG:** HRS-7053 Injection

## Key facts

- **NCT ID:** NCT05983146
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-09-01
- **Primary completion:** 2025-05-30
- **Final completion:** 2025-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The sponsor's R\&D strategy is adjusted.
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05983146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05983146, "Phase I Study of HRS-7053 Injection in the Treatment of Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05983146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*